S
Suzanne Oparil
Researcher at University of Alabama at Birmingham
Publications - 941
Citations - 122414
Suzanne Oparil is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Blood pressure & Angiotensin II. The author has an hindex of 106, co-authored 885 publications receiving 113983 citations. Previous affiliations of Suzanne Oparil include Michigan State University & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
Joel M. Neutel,Stanley S. Franklin,Suzanne Oparil,Amitabha Bhaumik,Agata Ptaszynska,Pablo Lapuerta +5 more
TL;DR: Greater and more rapid BP reduction with irbesartan/HCTZ was achieved without additional side effects, and the mean difference between combination and monotherapy in seated diastolic BP and seated systolic BP was 4.7 mm Hg.
Journal ArticleDOI
Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.
TL;DR: A secondary analysis of BP efficacy data from a published study that directly compared recommended starting doses of four currently marketed ARB was performed and showed that the percentage of patients achieving the combined SBP/DBP goal rate of <140/90 mm Hg was highest with olmesartan medoxomil.
Journal ArticleDOI
Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.
TL;DR: Combination antihypertensive therapy with AML+OM±HTCZ, up‐titrated as necessary, allowed a majority of patients to achieve BP goal, and study medication was safe and well tolerated.
Journal ArticleDOI
Hypertensive Therapy: Part II
TL;DR: Evidence suggests that weight loss interventions produce BP benefits that persist even after cessation of active therapy, and emphasis should be placed on prevention of weight gain, particularly in younger individuals with prehypertension and in families with a high prevalence of hypertension.
Journal ArticleDOI
Mechanism of Pulmonary Conversion of Anglotensin II to Angiotensin II in the Dog
TL;DR: Observations indicate that pulmonary conversion in vivo and plasma conversion in vitro occur via a dipepridylcarboxypeptidase and that a D-amino acid at the C-terminus prevents conversion.